Read by QxMD icon Read

Urologic Oncology

Chenming Zhao, Yuri Tolkach, Doris Schmidt, Michael Muders, Glen Kristiansen, Stefan C Müller, Jörg Ellinger
OBJECTIVE: Noncoding RNAs play an important role in carcinogenesis; a number of tRNA-halves are expressed in response to androgen stimulation and are involved in prostate cancer (CaP) initiation and progression. In this study, we evaluated the expression profile of androgen-dependent tRNA-halves in CaP. MATERIALS AND METHODS: Total RNA was isolated from formalin-fixed paraffin-embedded 58 CaP, and 25 benign prostate hyperplasia tissues. We also studied the expression in serum from 49 localized and 21 metastatic castration-resistant CaP samples...
September 9, 2018: Urologic Oncology
William K Oh, Wendy Y Cheng, Raymond Miao, Francis Vekeman, Marjolaine Gauthier-Loiselle, Mei Sheng Duh, Edward Drea, Ted P Szatrowski
OBJECTIVE: This retrospective observational study assessed if second-line chemotherapy vs. androgen receptor-targeted agents (ARTAs; abiraterone/enzalutamide) is associated with improved outcomes in metastatic castration-resistant prostate cancer (mCRCaP) patients who experience early progression on first-line ARTAs in a US community setting. METHODS: Patients with mCRCaP (n = 345) who progressed ≤ 12 months after first-line ARTA and received second-line chemotherapy (docetaxel/cabazitaxel; n = 147) or ARTA (n = 198) between May 2011 and October 2014 were identified...
September 7, 2018: Urologic Oncology
Venkatesh Kolluru, Balaji Chandrasekaran, Ashish Tyagi, Adnan Dervishi, Murali Ankem, Xiaofang Yan, Kong Maiying, Houda Alatassi, Saad P Shaheen, Ahmed Haddad, Chendil Damodaran, Jamie C Messer, Angelena Edwards
BACKGROUND: Prostate-specific antigen screening for prostate cancer (CaP) remains controversial. This study establishes the role of microRNA 301a (miR-301a) as a supplemental biomarker that can distinguish between patients with benign prostate hyperplasia and clinically significant CaP. We evaluate the ability of miR-301a to predict the adverse pathology of CaP. METHODS: In the first cohort, serum and prostate tumor samples were obtained from thirteen patients with benign prostatic hypertrophy (BPH), twelve patients with Gleason 6, and sixteen patients with Gleason 7 prostate adenocarcinoma...
September 5, 2018: Urologic Oncology
Kevin R Loughlin
No abstract text is available yet for this article.
September 4, 2018: Urologic Oncology
Simon P Kim, Neal J Meropol, Cary P Gross, Jon C Tilburt, Badrinath Konety, James B Yu, Robert Abouassaly, Christopher J Weight, Stephen B Williams, Nilay D Shah
INTRODUCTION: Genetic testing has been recently put forth as a strategy to improve decision-making in the management of localized prostate cancer. Little is known about how frequently prostate cancer specialists are using these tests, or whether they consider them important or effective. We performed a national survey of radiation oncologists and urologists on their perceptions and self-reported use of genetic testing. METHODS: From January to July 2017, a 4-wave mail survey was performed involving 915 radiation oncologists and 940 urologists about genetic testing and decision-making for localized prostate cancer...
September 3, 2018: Urologic Oncology
Alireza Aminsharifi, Ariel Schulman, John Anderson, Laura Fish, Kevin Oeffinger, Kevin Shah, Christina Sze, Kae J Tay, Efrat Tsivian, Thomas J Polascik
PURPOSE: In response to controversy regarding prostate cancer (CaP) screening recommendations, a consolidated Duke Cancer Institute (DCI) multidisciplinary algorithm for CaP screening was developed and implemented. We conducted an online survey within the year following its implementation to assess primary care provider (PCP) attitudes and adoption as well as to evaluate how this program affects screening rates. METHODS: A web-based 18-item survey was programmed and was electronically mailed to practicing PCPs at clinics affiliated with the Duke Primary Care system...
August 28, 2018: Urologic Oncology
André Steven, Sandra Leisz, Sebastian Fussek, Behdokht Nowroozizadeh, Jiaoti Huang, Daniel Branstetter, William C Dougall, Martin Burchardt, Arie S Belldegrun, Barbara Seliger, Allan Pantuck, Nils Kroeger
BACKGROUND: Inhibition of the receptor activator of NF-κB ligand (RANKL) has become a standard of care supportive treatment to prevent skeletal related events in cancer patients. Moreover, RANKL inhibition has been implicated with better survival outcome in lung cancer, while RANKL expression induces tumor progression and metastatic spread in vivo in breast cancer. Whether RANK/RANKL may have an impact on the pathogenesis of clear cell renal cell carcinoma (ccRCC) is currently unknown...
August 28, 2018: Urologic Oncology
Ari Bernstein, Ethan B Fram, Alexander Sankin, Evan Kovac, Abhishek Srivastava, Joseph DiVito, Joshua M Stern
INTRODUCTION: Recent studies have proposed that nearby fat deposits may have metabolic influence on kidney cancer pathobiology. Both fat quantity and quality may play unique roles in this complex relationship. As such, we investigated whether perinephric fat surface area (PFA), a quantitative measure of fat, or Mayo Adhesive Probability (MAP) score, a qualitative measure, were predictive of malignant pathology or Fuhrman grade in small renal masses. METHODS: A total of 317 patients undergoing minimally invasive partial nephrectomy between 2010 and 2016 for renal masses were retrospectively reviewed...
August 27, 2018: Urologic Oncology
Nathan A Brooks, Riley S Boland, Michael E Strigenz, Sarah L Bell, James A Brown
OBJECTIVES: Robot-assisted laparoscopic prostatectomy (RALP) and radical retropubic prostatectomy (RRP) provide similar outcomes in terms of biochemical recurrence, postoperative continence, and erectile function. Little is known about other complications of these procedures. To further address this, we examined patient outcomes at our institution over an 11-year period. METHODS: A retrospective review of 1,113 prostatectomies (646 RALP and 467 RRP) performed over 11 years by 9 different urologists at a single U...
August 25, 2018: Urologic Oncology
Nachiketh Soodana-Prakash, Tulay Koru-Sengul, Feng Miao, Diana M Lopategui, Luis F Savio, Kevin J Moore, Taylor A Johnson, Mahmoud Alameddine, Marcelo Panizzutti Barboza, Dipen J Parekh, Sanoj Punnen, Mark L Gonzalgo, Chad R Ritch
OBJECTIVE: To determine whether a specific lymph node yield (LNY) affects overall survival (OS) in patients with penile cancer. MATERIALS AND METHODS: Using the National Cancer Database, we identified 364 men diagnosed with pSCC who underwent ILND between 2004 and 2013. Men diagnosed on autopsy or at the time of death, patients with preoperative chemotherapy or radiotherapy, M+ and N3 disease, or with less than 3-month of follow-up were excluded. Kaplan-Meier analysis was used to compare Overall Survival (OS)...
August 21, 2018: Urologic Oncology
Bin Wang, Yanan Gu, Ke Hui, Jun Huang, Shan Xu, Shiqi Wu, Lei Li, Jinhai Fan, Xinyang Wang, Jer-Tsong Hsieh, Dalin He, Kaijie Wu
BACKGROUND: AKR1C3, as a crucial androgenic enzyme, facilitates intratumoral androgen biosynthesis and androgen receptor activation in castration-resistant prostate cancer (PCa). The data has shown that AKR1C3 expression is significantly elevated in clinical metastatic PCa specimens, indicating a potential role of AKR1C3 in PCa metastasis. METHODS: C4-2, 22RV1-T, and PC-3 cells with higher AKR1C3 expression were selected and treated with several specific AKR1C3 shRNAs or small molecule inhibitor, and the cell migration and invasion abilities were detected by wound healing assay and Transwell assay...
August 20, 2018: Urologic Oncology
Manabu Miki, Kenichiro Ishii, Takeshi Sasaki, Manabu Kato, Shinya Kajiwara, Hideki Kanda, Kiminobu Arima, Yoshifumi Hirokawa, Masatoshi Watanabe, Yoshiki Sugimura
BACKGROUND: In nonmuscle invasive bladder cancer patients, prediction of pTa and pT1 bladder cancer recurrence and progression must be established. Micropapillary structures have been defined as small clusters of invasive cancer cells having features of the epithelial-mesenchymal transition. Since the stromal microenvironment helps to induce the epithelial-mesenchymal transition, interactions between cancer cells and stroma should be closely examined to predict the tumorigenic phenotype of human bladder cancer cells...
August 20, 2018: Urologic Oncology
Philipp Gild, Stephanie A Wankowicz, Akshay Sood, Nicolas von Landenberg, David F Friedlander, Shaheen Alanee, Felix K H Chun, Margit Fisch, Mani Menon, Quoc-Dien Trinh, Joaquim Bellmunt, Firas Abdollah
OBJECTIVES: To examine the impact of race on quality of care and overall survival (OS) among patients with muscle invasive bladder cancer (MIBC) treated with radical cystectomy (RC) in the U.S. MATERIALS & METHODS: Our cohort consisted of 12,652 patients receiving RC for MIBC within the National Cancer Database from 2004 to 2012. Patients were stratified by race (Black non-Hispanic vs. White non-Hispanic) and imbalances in patient characteristics mitigated using propensity score weighting...
August 20, 2018: Urologic Oncology
Mohamed Kamel, Naleen Raj Bhandari, Rodney Davis, Nalin Payakachat
BACKGROUND: Health-related quality of life (HRQOL) among elderly Americans diagnosed with upper tract urothelial cancer (UTUC) is unknown. We compared HRQOL in patients from before and after UTUC diagnosis and among different tumor stages after UTUC diagnosis using the Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey database. MATERIALS AND METHODS: This cross-sectional study used the 14 cohorts (1998-2013) of Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey to identify elderly Americans (≥65years) diagnosed with UTUC and with completed HRQOL surveys (the Short Form-36 or Veterans Rand-12)...
August 19, 2018: Urologic Oncology
Peter J Goebell, Lothar Müller, Andreas Hübner, Hanns-Detlev Harich, Emil Boller, Michaela Koska, Martina Jänicke, Norbert Marschner
OBJECTIVES: A high body mass index (BMI) is associated with an increased risk for developing renal cell carcinoma (RCC), a higher complication rate after surgery, and a postoperative decline in renal function after nephrectomy. In contrast, a high preoperative BMI has been associated with increased survival in patients with localized RCC. We examined the prognostic impact of the BMI in patients treated for metastatic RCC (mRCC) in daily routine practice in Germany. PATIENTS AND METHODS: The ongoing prospective, multicenter German clinical cohort study on mRCC (RCC-Registry) has recruited patients from more than 110 oncology/urology outpatient centers and hospitals at initiation of systemic first-line treatment...
August 18, 2018: Urologic Oncology
Kosuke Ueda, Shigetaka Suekane, Hirofumi Kurose, Katsuaki Chikui, Makoto Nakiri, Kiyoaki Nishihara, Mitsunori Matsuo, Akihiko Kawahara, Hirohisa Yano, Tsukasa Igawa
OBJECTIVE: In renal cell carcinoma (RCC), several prognostic biomarkers have been identified and are under investigation. Several reports have shown that the expression of programmed death 1 (PD-1) and its ligand PD-L1 is associated with poor outcome for patients with RCC. The present study is aimed at evaluating the expression of PD-1 and PD-L1 and to investigate their clinical and prognostic significance in patients with clear cell RCC (CCRCC) having received molecular targeted therapies...
August 18, 2018: Urologic Oncology
Yu-Wei Chen, Moshe C Ornstein, Laura S Wood, Kimberly D Allman, Allison Martin, Jennifer Beach, Timothy Gilligan, Jorge A Garcia, Brian I Rini
BACKGROUND: Improved overall survival of cancer patients treated by high-volume providers has been reported in surgical oncology and radiation oncology literature. Whether this volume-outcome association exists in medical oncology-managed metastatic solid tumors is uncertain. This study aimed to investigate the effect of facility case volume (FCV) on overall survival in patients with metastatic renal cell carcinoma (mRCC) diagnosed in the targeted therapy era. MATERIALS AND METHODS: Adult patients diagnosed with mRCC between 2006 and 2015 were identified in the National Cancer Database...
August 18, 2018: Urologic Oncology
Ajay Gopalakrishna, Andrew Chang, Thomas A Longo, Joseph J Fantony, Michael R Harrison, Paul E Wischmeyer, Brant A Inman
PURPOSE: A nutritious diet has been associated with better health-related quality of life (HRQOL) in a variety of cancer survivors. However, little is known about dietary habits and its association with HRQOL in bladder cancer survivors. The objective of this cross-sectional study is to describe dietary intake patterns and its relationship to HRQOL in a large cohort of bladder cancer survivors. METHODS: Bladder cancer survivors within our institutional database were mailed surveys to assess dietary intake patterns utilizing the Diet History Questionnaire II and assessing HRQOL utilizing the Functional Assessment of Cancer Therapy-Bladder Cancer...
August 17, 2018: Urologic Oncology
Greg Kauffmann, Fauzia Arif, Pritesh Patel, Aytek Oto, Stanley L Liauw
PURPOSE: The purpose of this study was to investigate the utility of pre-treatment multiparametric magnetic resonance imaging (mpMRI) in a modern cohort of intermediate and high-risk prostate cancer patients treated with primary radiotherapy. METHODS AND MATERIALS: One hundred twenty three men with National Comprehensive Cancer Network (NCCN) intermediate or high-risk prostate cancer were treated with primary EBRT and/or brachytherapy and had evaluable pre-treatment mpMRI with endorectal coil...
August 16, 2018: Urologic Oncology
Inês Anselmo da Costa, Jörg Hennenlotter, Viktoria Stühler, Ursula Kühs, Marcus Scharpf, Tilman Todenhöfer, Arnulf Stenzl, Jens Bedke
BACKGROUND: Prostate cancer (CaP) is the most common nonepidermal cancer in elderly males. Due to its heterogeneity and high variability in regards to clinical outcome and therapeutic response, urologists' handling of this disease remains a challenge. The objective of this study was to assess Transketolase like 1 (TKTL1) expression in benign prostatic tissue, peritumoral tissue and in CaP (in different stages of disease), and its correlation with clinicopathological findings, in order to detect if TKTL1 expression is associated with CaP tumorigenesis...
August 14, 2018: Urologic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"